Chronic Lymphocytic Leukemia | Specialty

Dr. Woyach on Phase II Trial of MOR208 Trial in CLL

February 18th 2017

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

February 10th 2017

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL

February 10th 2017

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.

Dr. Woyach on Preliminary Efficacy Results of MOR208 Trial in CLL

February 7th 2017

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the preliminary efficacy results of the MOR208 trial in chronic lymphocytic leukemia (CLL).

Upfront Ibrutinib Continues to Impress in CLL

February 3rd 2017

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

February 3rd 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Dr. Tam Discusses BTK Inhibition in CLL

February 3rd 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

MOR208 Combo Regimens Show Early Promise in CLL

January 27th 2017

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

Dr. Leis on Promising Combo Regimens Being Explored in CLL

January 24th 2017

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

Dr. Tam on BTK Inhibitor BGB-3111 in CLL

January 21st 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BGB-3111, a new BTK inhibitor being used in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Woyach on Ibrutinib Resistance in CLL

January 21st 2017

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

Dr. Leblond on Treatment Landscape of CLL

January 20th 2017

Veronique Leblond, MD, of Pietra - Hospital, Paris, France, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).

BTK Inhibitors Mushroom in Blood Cancer Field

January 20th 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

January 18th 2017

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.

Frontline Ibrutinib Benefit Sustained in Pivotal CLL Trial Update

January 17th 2017

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

January 14th 2017

Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.

The Future of Treatment of B-Cell Lymphoma

January 13th 2017

DLBCL: CAR-T as Curative Treatment/Bridge to Transplant

January 13th 2017

CAR-T Therapy for DLBCL

January 13th 2017

Relapsed/Refractory DLBCL

January 13th 2017